Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene blue added to empagliflozin for diabetic nephropathy
IRCT20191228045924N7Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetic glomerulosclerosis comparing Intervention: empagliflozin + methylene blue with Control: empagliflozin (2 arms). Primary endpoints: Reduction in microalbuminuria and Improvement in glomerular filtration rate. Started Nov 2023; status: completed.
02
Drugs
methylene blueempagliflozin
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on IRCT20191228045924N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191228045924N7.